

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 00052643

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-31 09:28

Reviewer performed review: 2020-02-03 11:48

Review time: 3 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

"Medications in Type-2 Diabetics And Their Association With Non-alcoholic Fatty Liver Disease Related Advanced Fibrosis" is an interesting article. Authors' findings are not only innovative, but also important as cited medications are very common in clinical practice and clinicians must be aware of their associations with advanced fibrosis. Overall, it is a good work. However I think some modifications concerning language and layout (not exactly compliant BPG guidelines) would be necessary before publication.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 00507108

Position: Peer Reviewer

Academic degree: FACP, FRCS (Ed), MD

Professional title: Professor, Doctor

Reviewer's Country/Territory: Ireland

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-02-03 18:29

Reviewer performed review: 2020-02-04 11:24

Review time: 16 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

29 January 2020 Correlation of leptin and Vaspin in newly diagnosed Type 2 Diabetes. The association of leptin with fat mass and insulin resistance is well known. The relationship between Leptin and atherosclerosis less definite but as the Authors write animal experiments suggest that this may be the case . I was unable to find ref 3 in Pub med but the Authors should distinguish between animal and human studies .. The Authors should consider a paragraph in the introduction on the impact of gender and menopause on Leptin and Vapin. The results are given in Tables and Figures but my copy did not have figures.. There is no text with a description of the results which is unusual. Tables and figures probably not sufficient for easy understanding of the findings. The Authors should consider a description of the main results in a text format as well as the tables and figures, in the results section rather than in the discussion and the discussion section becomes discussion of the results. It would be interesting to see a graph of leptin and Vaspin against BMI as compared to Waist/hip ratio as fat mass is better represented by waist/hip rather than BMI in Indians. I am not clear what the Authors mean when quoting Brennan . The Brennan paper does not discuss adipocyte dysfunction but is a report on the relationship between leptin and CVD,

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 03293832

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Senior Research Fellow

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-31 18:50

Reviewer performed review: 2020-02-05 03:13

Review time: 4 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

The manuscript describes the relationship between liver fibrosis and various medications in in patients with biopsy-proven NAFLD and type 2 diabetes using their own hospital records. Authors concluded 'being on metformin, liraglutide, lisinopril, hydrochlorothiazide, atorvastatin and simvastatin is associated with less likelihood of advanced fibrosis, while using furosemide and spironolactone increased the risk of advanced fibrosis'. The manuscript is well written and contents are novel and worth publication in WJG. I only suggest that authors avoid to declare 'using furosemide and spironolactone increased the risk of advanced fibrosis' and soften the expression, because there is a limitation of the present work as authors themselves mention in the last part of Discussion. Minor comments 1. Please write in full LKB1 (liver kinase B1) and HSCs (hepatic stellate cells). No abbreviation will be necessary because those words are used once in the text. 2. Please add the explanation of mo (month) in Table 2. 3. Please add the explanation of the numbers 81 and 325 in aspirin dose in Table 2.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 01919991

Position: Peer Reviewer

Academic degree: MSc, PhD

Professional title: Research Scientist

Reviewer's Country/Territory: Italy

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: AI Technique

Reviewer accepted review: 2020-01-31 05:18

Reviewer performed review: 2020-02-07 07:53

Review time: 7 Days and 2 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

The study by Siddiqui and coworkers is a retrospective cohort study to assess the association between master medications used in diabetes and advanced fibrosis in patients with biopsy-proven NAFLD and T2D. The topic is interesting given the prevalence of the two pathologies NAFLD and TD2 and the relationships between them. The quality of the manuscript is adequate and, although further studies are needed, the results could have a potential impact on the clinical practice of drug treatment of diabetic patients at risk or with overt NAFLD. In my opinion, for the sake of greater disclosure, the authors should extend the information on published studies on appropriate antidiabetic treatments (oral or injectable) that can improve NAFLD. I refer, citing only a few as an example: Hazlehurst et al, 2016, doi.org/10.1016/j.metabol.2016.01.001; Xia & Gao, 2019, [doi: 10.3389/fphar.2019.00877](https://doi.org/10.3389/fphar.2019.00877); Dharmalingam & Yamasandhi, 2018, [doi: 10.4103/ijem.IJEM_585_17](https://doi.org/10.4103/ijem.IJEM_585_17); 10.4103/ijem.IJEM_585_17.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 03293832

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Senior Research Fellow

Reviewer's Country/Territory: Japan

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: Yu-Qiao Wang (Quit in 2020)

Reviewer accepted review: 2020-04-02 03:18

Reviewer performed review: 2020-04-02 06:18

Review time: 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Authors addressed comments appropriately.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54448

Title: Medications in type-2 diabetics and their association with liver fibrosis

Reviewer's code: 00052643

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: United States

Manuscript submission date: 2020-01-31

Reviewer chosen by: Yu-Qiao Wang (Quit in 2020)

Reviewer accepted review: 2020-04-02 08:20

Reviewer performed review: 2020-04-02 08:25

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The paper is now suitable for publication, as authors have done the suggested



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

modifications.